Differentiated thyroid carcinoma

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

10 events
Dec 2026COACH - Comparing Two Different Methods to Suppress Thyrotropin in Patients With Advanced Thyroid Cancer

AHS Cancer Control Alberta — PHASE2

TrialNOT YET RECRUITING
Sep 2026Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy

University Medical Center Groningen

TrialNOT YET RECRUITING
Apr 2026Anlotinib and Benmelstobart in DTC

Fudan University — PHASE2

TrialNOT YET RECRUITING
Apr 2026Empirical Radioactive Iodine Therapy in DTC

Assiut University — PHASE1, PHASE2

TrialNOT YET RECRUITING
Jan 2026A Phase I Trial of Af-001 in Patients With Differentiated Thyroid Cancer

Alpha Fusion Inc. — PHASE1

TrialRECRUITING
Nov 2025Desiccated Thyroid Extract Combined With Levothyroxine for TSH Suppression Therapy in DTC

West China Hospital — PHASE3

TrialNOT YET RECRUITING
Nov 2025F-18 Tetrafluoroborate PET/CT in Differentiated Thyroid Cancer

Ankara University — NA

TrialRECRUITING
Oct 2025Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)

Washington University School of Medicine — PHASE2

TrialRECRUITING
Oct 2025Testing a Web-based Intervention for Radioactive Iodine Symptom Management to Improve Health-related Quality of Life Among Differentiated Thyroid Cancer Patients

Georgetown University — NA

TrialRECRUITING
Aug 2025Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyroid Cancer

Georgetown University — NA

TrialRECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

3 programs

FINANCIAL LANDSCAPE SUMMARY

3

Total programs

3

Open now

3

Copay cards

Copay Assistance3

RETEVMO

Eli Lilly

OpenContact for detailsApply ↗

Thyrogen

Sanofi

OpenContact for detailsApply ↗

Lenvima

Eisai

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

3 FDA-approved

Thyrogen

(Thyrotropin alfa)Orphan drugstandard

Genzyme Corporation

Thyroid Stimulating Hormone [EPC]

12.1 Mechanism of Action Thyrotropin (TSH) is a pituitary hormone that stimulates the thyroid gland to produce thyroid hormone. Binding of thyrotropin...

FDA label ↗

CABOMETYX

(cabozantinib)Orphan drugstandard

Exelixis, Inc.

12.1 Mechanism of Action In vitro biochemical and/or cellular assays have shown that cabozantinib inhibits the tyrosine kinase activity of MET, VEGFR-...

FDA label ↗

LENVIMA

(lenvatinib)Orphan drugstandard

Eisai Inc.

Kinase Inhibitor [EPC]

12.1 Mechanism of Action Lenvatinib is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors V...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

9 active trials
1Phase 3
3Phase 2
2N/A
3Unknown
9Total recruiting
Search clinical trials for Differentiated thyroid carcinoma

Recent News & Research

No recent news articles indexed yet for Differentiated thyroid carcinoma.
Search PubMed for Differentiated thyroid carcinoma

Browse all Differentiated thyroid carcinoma news →

Specialist Network

Top 6 by expertise

View all Differentiated thyroid carcinoma specialists →

Quick Actions